The expression of CLDN5, as measured by immunohistochemistry and quantitative PCR, is decreased in patients with schizophrenia and depression according to postmortem analysis (Greene et al., 2020; Lizano et al., 2022). This evidence concerns the gene CLDN5 and schizophrenia.